key: cord-0730174-9pzjwcl1
authors: Koca Kalkan, Ilkay; Ates, Hale; Aksu, Kurtulus; Yesilkaya, Selma; Topel, Musa; Cuhadar Ercelebi, Dilek; Turkyilmaz, Suleyman; Oncul, Ali; Demir, Senay
title: Real-life adherence to subcutaneous immunotherapy: What has changed in the era of the COVID-19 pandemic
date: 2021-06-08
journal: World Allergy Organ J
DOI: 10.1016/j.waojou.2021.100558
sha: 3c199b8d922f8371faa38fd1f7afebb977195874
doc_id: 730174
cord_uid: 9pzjwcl1

Background Allergen immunotherapy (AIT) must be continued for 3 years, to achieve a long-term modifying effect. Adherence is a key to ensure effectiveness. The objective of this study was, first of all, to evaluate the adherence with subcutaneous immunotherapy (SCIT) and to identify the main causes of SCIT withdrawal in real-life practice in our clinic. Secondly, to investigate to what extent COVID-19 pandemic altered our SCIT receiving patients’ treatment adherence behaviors and the factors that affected their decisions. Methods Retrospective analysis of the medical records of patients ages ≥18 years, who had started SCIT in January 2014 or later until September 2020 in our department for the diagnosis of allergic rhinitis, allergic asthma or venom allergy were included in the study. Adherence was determined as the accomplishment of three years of SCIT. Results A total of 124 patients (72 female [58.1%]; median age, 35 [19-77] years) were included. The adherence rate to SCIT in our tertiary center’s real-life setting was 56.25% with a follow-up duration of 3 years before COVID-19 pandemic. Dose modification, defined as reducing patient's planned SCIT dose due to a systemic allergic/large local reaction or missed injection, and its frequency, which is the number of dose adjustments done throughout the SCIT, was found to be the only factor related to nonadherence. But with the pandemic only in 6 months, among 63 patients receiving SCIT, 15 patients (23.81%) dropped out and the most common reason was fear of being infected with COVID-19 virus during receiving SCIT in hospital (93.33%). The only independent predictor of drop-out during COVID-19 pandemic was short duration of AIT (p=0.012). When we compare the dropped-out cases before and after the start of pandemic AIT duration was significantly shorter in pandemic period (p= 0.005). Conclusion Adherence rate to SCIT in our real-world setting study was 56.25% before COVID-19 pandemic. Our results indicated that patients requiring dose modification were more prone to be non-adherent. Approximately a quarter of patients dropped-out with the start of pandemic, almost all due to fear of being infected during receiving SCIT in hospital. Since short SCIT follow-up time was found to be the only risk factor for drop-out during COVID-19 pandemic, we believe that patients who are in the early phases of their treatment should be observed more closely and their concerns should be answered by their doctors.

Allergen immunotherapy (AIT) has been used to treat allergic diseases like allergic rhinitis, allergic asthma and venom allergies for over a century by inducing and maintaining first confirmed case until end of September 2020, during a six months period. The reasons for 118 SCIT drop out after COVID-19 pandemic were also evaluated. 119 The diagnoses and treatment of AR, asthma and venom allergy were appropriate 120 according to current guidelines; the Allergic Rhinitis and its Impact on Asthma (ARIA), 121 Global Initiative for Asthma (GINA) and European Academy of Allergy and Clinical 122 Immunology (EAACI) guidelines, respectively (19) (20) (21) . 123 A written informed consent was obtained from all patients before initiating SCIT. 124 Clustered or conventional immunotherapy schedules with premixed or single allergen extracts 125 were used. In the clustered schedule, two or three injections per visit per week were applied to 126 reach the maintenance dose in 6 weeks. The conventional method with purified depot 127 preparations was consisted of one injection per visit every week to reach the maintenance 128 dose in 16 weeks. But the conventional method with allergoid immunotherapy extracts was 129 applied one injection every week for a total of 7 weeks to reach the maintenance dose. The 130 maintenance dose was administered at 4-6-week intervals over a period of 3 to 5 years.

During full SCIT course all injections were administered by trained nurses with supervision of 132 a doctor in our allergy clinic, equipped with material for emergency resuscitation. All patients 133 were evaluated before and 30 minutes after the SCIT administration, also each injection was 134 recorded. 135 The patients' records were reviewed and any subject who missed at least 2 consecutives 136 planned SCIT dosses between subsequent injections was defined as noncompliant. Adherence 137 was determined as the accomplishment of three years of SCIT. Patient who had 8 consecutive 138 week delay from the build-up phase or 16 consecutive week delay from the maintenance 139 phase was defined as dropped-out (22). The patient's reason for dropping out SCIT during the (Table 3) .

A binary logistic regression analysis was performed to determine the independent factor 197 associated with SCIT drop-out during the COVID-19 pandemic, with the defined borderline 198 significant factors (p=0.012). As a result, AIT duration was the only factor identified ( Table   199 4). 200 We further compared the characteristics of drop-outs from SCIT before and during the 201 COVID-19 pandemic period. AIT duration was significantly shorter in the drop-outs during 202 the COVID-19 pandemic period (p= 0.005) ( Table 5 ).

Cumulative proportions of patients who continue allergen immunotherapy over time was 204 analyzed using Kaplan-Meier curves ( Figure 2 ).

Our study showed that the adherence rate to SCIT in our tertiary center's real-life 207 setting is 56.25% with a follow-up duration of 3 years before COVID-19 pandemic. Dose 208 modification and its frequency is found to be the only factor related with nonadherence. In 209 accord with this finding, we observed that occurrence of dose modification increases the risk 210 for nonadherence for overall drop-outs (27.42%) of whole group before COVID-19 pandemic. from first year, 8 patients (53.3%) were from second year and none was from third year of SCIT treatment. When we compare the dropped-out cases before and after the start of 217 pandemic AIT duration was significantly shorter in pandemic period (p= 0.005).

Adherence rates for SCIT from controlled studies are noticeably high, but they are 219 partially biased, as patients are strictly selected, instructed and observed. In order to retrieve 220 more reliable data real-life studies are important (8). The adherence rate of previous real-life 221 SCIT studies in adults ranges between 23-88%, most of them being <70%, in line with our 222 work (6, 23). Our patients observed adherence rate of 56.25% is also comparable with other 223 chronic diseases like cardiovascular disease, which is approximately 50% (24). In our large 224 tertiary allergy clinic patients are examined before and 30 minutes after each injection by the 225 allergist, and the same allergy nurses apply the shots. Also, all of our SCIT patients had 226 government-assisted health insurance. Even though we have a close cooperation with the 227 patients and the cost is covered by health insurance our discontinuation rate is higher than another. Therefore, to be able to evaluate the changing adherence pattern of our SCIT 239 patients' we compared the factors in two different time-zones, before and during COVID-19 240 pandemic, in the same clinic.

In this study, no statistical differences were found between adherent and non-adherent (27). But others found no correlation between adherence and 252 diagnosis (12, 13, 25). The use of shorter build-up phase seemed to improve patients' 253 adherence to SCIT in one study, but in our study AIT build-up scheme showed no impact on 254 adherence (28).

Overall, in our study clinical factors like local or systemic reactions, need for 256 premedication and noncompliance did not play a significant effect on adherence. Similar to 257 our study, in their study Yang et al. found no difference between the adherent and 258 nonadherent group in terms of the incidence of adverse reactions (13). Also, when we look at 259 patient-reported reasons for SCIT nonadherence, in a review of more than 25 studies it 260 appears as that local and systemic reactions are not the main reasons for discontinuation (4% 261 and 1-16% respectively) (10). However, in our study, the only factor found related to 262 nonadherence was need for dose modification and its frequency. The dose modification was 

The key elements of an effective AIT adherence intervention plan come from 293 providing sufficient and effective education and information about health, illness, and 294 treatment steps including dose adjustments; incorporation of standardized follow-up visits, 295 and especially now in the era of the COVID-19 pandemic employment of telecommunication 296 technologies with a communication strategy composed of patient-centered care, shared 297 decision making, and motivational interviewing strategies to the patient (32, 33). Not a one-298 size-fits-all education, but a tailored one according to patient's health literacy level should be 299 delivered to achieve the best adherence. The necessity of effective education for improving 300 SCIT adherence was shown in a study which was executed in five countries (USA, France, 301 Spain, Germany, and Russia) involving 261 patients. The participants, who were either recent 302 nonadherents or "non-starters" (having decided not to initiate AIT recommended by their 303 physician), completed an internet survey before and after a new communication template on 304 allergy and allergen immunotherapy was presented. The result was critical: 28% of the 305 participants weren't aware of the allergen they were receiving during AIT. Twenty-seven 306 percent reported that they had not been told allergy was a chronic condition. Early abandoners 307 held its low effectiveness (39 %) and expense (39 %) responsible for therapy discontinuation.

After new communication template, participants of the survey felt much more enlightened and 309 more likely to start or fulfill AIT (34). As a result, this research clearly reveals that a lack of 310 education in AIT patients hampers treatment success. Also, increasing medical data 311 demonstrates the importance of pre-AIT education, clinic telephone follow-up calls and more 312 frequent clinic visits for improving adherence to AIT (35-37). Although there is a close 313 relationship between allergist and their patients in our clinic, since the same allergy team 314 (doctors and nurses) observes the patients at each shot and discusses their therapy route, the rate of adherence was not as high as expected, dose modifications being as the major cause. In 316 fact, during routine visits, it is difficult to arrange a structured educational program, and our 317 results prove it. To be effective, doctors might be planned to optimize the time for education 318 during a consultation. Additional investigations are needed from prospective studies, where 319 we can get more detailed information addressing this dimension of adherence.

This study is limited by its retrospective design and single-institutional small sample 321 size. More evidence is needed from larger samples in prospective studies. Also, because of the 322 new and ongoing nature of COVID-19 pandemic, some of the patient's SCIT from the 323 pandemic group is still ongoing. We were only able to give drop-out rate but not adherence 324 rate, for this group. In spite of these limitations, this is the first adult study comparing the 325 effect of COVID-19 pandemic on SCIT adherence attitudes. Table 1 : Clinical characteristics and demographic data of the SCIT patients before CoVID-19 451 pandemic. Patients whose initiation date was between January 2014 -February 2017 n=48

Patients whose initiation date was after March 2017 n=76

Patients dropped-out before COVID-19 pandemic n=13

Patients receiving SCIT treatment when COVID-19 pandemic started n=63 

One hundred years of allergen immunotherapy: time to ring